Medication Adherence and FDA: A Q&A With Safe Use Head
This article was originally published in RPM Report
Executive Summary
One of the many stakeholders involved with the National Consumers League’s adherence campaign is FDA, through CDER’s Safe Use Initiative, CDER’s Office of Communication and FDA’s Office of Women’s Health. Here is an email Q&A with Safe Use Initiative Director Karen Weiss for more details on FDA’s role in Script Your Future and medication adherence more broadly.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.